Thursday, July 9, 2026

biotech · Cervical Spinal Cord Injury · Spinal Cord Injury · LCTX

Lineage Cell Therapeutics

Lineage Cell Therapeutics is a biotech organization headquartered in Carlsbad, USA. It trades on NYSE under ticker LCTX. Primary therapeutic focus areas include Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cor

Carlsbad, USA HQ
1990 Founded
35 Employees
Public company Type
LCTX · NYSE Ticker
Company details
Status
Public
HQ
Carlsbad, USA
Founded
1990
Employees
35
Programs
3
Drugs
0
Patents
0
Clinical program

OPC1

Phase 1 · mab · Spinal Cord Injury Cervical

OPC1 for Spinal Cord Injury Cervical is a Phase 1 program (mab) at Lineage Cell Therapeutics with 1 ClinicalTrials.gov record(s).

Internal code LCTOPC1-SCI-03

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lineage Cell Therapeutics
Phase
Phase 1
Modality
mab
Indication
Spinal Cord Injury Cervical
Status
active
Trials
1

Clinical trials